Mon panier

SLAMF7

SLAMF7 Informations sur la molécule

Nom anglaisSLAM family member 7Nombre de médicaments commercialisés1
Nombre de médicaments cliniques8Alias de la cibleCS1,UNQ576/PRO1138,SLAMF7,Novel Ly9,SLAM Family Member 7,Membrane Protein FOAP-12,CD2 Subset 1,Protein 19A,CRACC,CD2-Like Receptor Activating Cytotoxic Cells,CD2-Like Receptor-Activating Cytotoxic Cells,19A24 Protein,CD319,19A,CD319 Antigen,Novel LY9 (Lymphocyte Antigen 9) Like Protein
Phase de R&D la plus avancéeApproved
Nom anglaisSLAM family member 7
Alias de la cibleCS1,UNQ576/PRO1138,SLAMF7,Novel Ly9,SLAM Family Member 7,Membrane Protein FOAP-12,CD2 Subset 1,Protein 19A,CRACC,CD2-Like Receptor Activating Cytotoxic Cells,CD2-Like Receptor-Activating Cytotoxic Cells,19A24 Protein,CD319,19A,CD319 Antigen,Novel LY9 (Lymphocyte Antigen 9) Like Protein
Nombre de médicaments commercialisés1
Nombre de médicaments cliniques8
Phase de R&D la plus avancéeApproved

SLAMF7 Liste de produits

  • Attribut

    Protein (8)

  • Bibliothèque de produits

    En ligne (8)

  • Espèces

    Human (6)Mouse (1)Rhesus macaque (1)

  • Étiquette

    His Tag (5)Fc Tag (1)His Tag & Avi Tag (1)Mouse IgG Fc Tag (1)

  • Marqueur

    Unconjugated (4)Biotin-labeled (1)FITC Labeled (1)PE Labeled (2)

SLAMF7Contexte de la molécule

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

SLAMF7Alias de la molécule

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital)Phase 2 ClinicalUniversity Hospital WürzburgMultiple Myeloma
Details
dual anti-CS-1/anti-BCMA CAR T-cell therapy (Wuhan Sian Medical Technology)Phase 1 ClinicalWuhan Sian Biotechnology Co LtdMultiple Myeloma
Details
BCMA-CS1 cCAR T-cell therapyPhase 1 ClinicaliCell Gene Therapeutics LLCMultiple Myeloma
Details
SA102-CAR-TSA-102; SA102Phase 1 ClinicalWuhan Sian Biotechnology Co LtdMultiple Myeloma
Details
WS-CART-CS1WS-CART-CS1Phase 1 ClinicalPaula C. & Rodger O. Riney Blood Cancer Research, Washington University School Of MedicineMultiple Myeloma
Details
MB-104MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CARPhase 1 ClinicalCity Of Hope National Medical CenterGlioblastoma; Multiple Myeloma; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
CS1 Targeted CAR T-cells (Yake Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co LtdMultiple Myeloma
Details
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology)ClinicalWuhan BioRaid Biotechnology Co LtdHematologic Neoplasms
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
ElotuzumabPDL-063; HuLuc-63; BMS-901608ApprovedAbbvie Inc, Bristol-Myers Squibb CompanyEmplicitiUnited StatesMultiple MyelomaBristol-Myers Squibb Company2015-11-30Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Leukemia, Plasma Cell; Lymphoma; Multiple Myeloma; Polycythemia Vera; Primary Myelofibrosis; Smoldering Multiple Myeloma; Thrombocythemia, Essential
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques